| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Biomarin Pharmaceutical Inc.'s insiders have reduced their positions by a net 17,557 shares worth roughly $1.2M.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 214.6K | $11.95M | - | |
| CFO | 123.3K | $6.86M | - | |
| VP | 84.1K | $4.68M | - | |
| VP | 61.0K | $3.40M | - | |
| Dir | 49.4K | $2.75M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 27, 2021 | Jean Jacques Bienaime68 | Chief Executive Officer | Sale+OE | 8,333 | $85.49 | $712,388.17 | -2.7% | |
| Dec 29, 2020 | Jean Jacques Bienaime68 | Chief Executive Officer | Sell | 3,000 | $88.48 | $265,425.00 | -1.0% | |
| Oct 14, 2020 | Jeffrey Robert Ajer58 | EVP, Chief Commercial Officer | Sell | 2,121 | $79.91 | $169,489.11 | -3.3% | |
| Aug 31, 2020 | David E I Pyott | Director | Buy | 12,800 | $78.26 | $1,001,715.06 | +71.3% | |
| Aug 3, 2020 | Michael G Grey49 | Director | Sale+OE | 2,500 | $120.35 | $300,875.00 | -5.5% | |
| Jul 20, 2020 | Henry J Fuchs | President, Worldwide R& D | Sale+OE | 126,389 | $130.00 | $16,430,570.00 | -55.1% | |
| Jul 13, 2020 | Henry J Fuchs | President, Worldwide R& D | Sale+OE | 23,011 | $130.00 | $2,991,430.00 | -18.3% | |
| Jun 26, 2020 | Willard H Dere | Director | Sell | 4,430 | $123.61 | $547,592.30 | -25.0% | |
| Jun 19, 2020 | Jeffrey Robert Ajer58 | EVP, Chief Commercial Officer | Sale+OE | 15,000 | $124.00 | $1,860,000.00 | -19.1% | |
| Jun 5, 2020 | V Bryan Lawlis53 | Director | Sell | 4,430 | $107.46 | $476,047.80 | -19.0% |